MX2022012229A - Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19. - Google Patents

Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19.

Info

Publication number
MX2022012229A
MX2022012229A MX2022012229A MX2022012229A MX2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A
Authority
MX
Mexico
Prior art keywords
treating
methods
negative effects
antibody compositions
reducing negative
Prior art date
Application number
MX2022012229A
Other languages
English (en)
Inventor
Pradip Nair
Monzón Kalet León
Jose Enrique Montero Casimiro
Shaw Kiran Mazumdar
Usha Bughani
Sandeep Nilkanth Athalye
Melarkode Subbaraman Ramakrishnan
Ramos Tania Crombet
Suzarte Mayra Ramos
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2022012229A publication Critical patent/MX2022012229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona el uso de anticuerpos anti-CD6 que se unen específicamente al dominio 1 de CD6 para tratar efectos de un coronavirus o agente bacteriano y particularmente COVID-19 y variantes del mismo. Los anticuerpos anti-CD6 de la presente invención presentan actividad terapéutica al reducir la respuesta inmunitaria hiperreactiva, como por ejemplo los altos niveles de expresión de citosinas.
MX2022012229A 2020-04-04 2021-04-03 Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19. MX2022012229A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (1)

Publication Number Publication Date
MX2022012229A true MX2022012229A (es) 2022-10-27

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012229A MX2022012229A (es) 2020-04-04 2021-04-03 Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19.

Country Status (15)

Country Link
US (1) US20230151107A1 (es)
EP (1) EP4126961A4 (es)
JP (1) JP2023526890A (es)
KR (1) KR20220165267A (es)
CN (1) CN115698071A (es)
AU (1) AU2021247258A1 (es)
BR (1) BR112022018936A2 (es)
CA (1) CA3174566A1 (es)
CL (1) CL2022002684A1 (es)
CO (1) CO2022014199A2 (es)
IL (1) IL296487A (es)
MX (1) MX2022012229A (es)
TW (1) TW202200202A (es)
WO (1) WO2021199006A1 (es)
ZA (1) ZA202210032B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce phosphorylation of cd6
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ­６의 길항제
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
AU2020415307A1 (en) * 2019-12-24 2022-06-09 F. Hoffmann-La Roche Ag Method of treating virus infection using a TLR7 agonist

Also Published As

Publication number Publication date
JP2023526890A (ja) 2023-06-26
BR112022018936A2 (pt) 2022-12-06
WO2021199006A1 (en) 2021-10-07
ZA202210032B (en) 2024-09-25
EP4126961A4 (en) 2024-07-17
CN115698071A (zh) 2023-02-03
TW202200202A (zh) 2022-01-01
AU2021247258A1 (en) 2022-11-10
KR20220165267A (ko) 2022-12-14
US20230151107A1 (en) 2023-05-18
EP4126961A1 (en) 2023-02-08
IL296487A (en) 2022-11-01
CA3174566A1 (en) 2021-10-07
CO2022014199A2 (es) 2022-11-08
CL2022002684A1 (es) 2023-03-24

Similar Documents

Publication Publication Date Title
ZA202210032B (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
SA520420801B1 (ar) أil جسام مضادة لـ -11
MY208545A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
EP4223774A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
ZA202209119B (en) Anti-human cd19 antibodies
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2023001564A (es) Terapias genicas para trastornos neurodegenerativos.
EP4445913A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
JOP20240198A1 (ar) أنظمة مضادة لـ vegf ممتدة عالية الجرعة لعلاج اضطرابات وعائية المنشأ بالعين
PH12021552555A1 (en) Dihydroorotate dehydrogenase inhibitors
PH12021552903A1 (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
PH12022550130A1 (en) Enzyme inhibitors
MX2025006615A (es) Metodos para alterar la composicion corporal
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
PH12022550118A1 (en) Enzyme inhibitors
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2025013942A (es) Anticuerpos contra mucina 16 y metodos de uso de los mismos
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2023010812A (es) Composiciones y metodos para tratar la nefritis lupica.
MX2022002069A (es) Inhibidores de enzimas.